Akt and autophagy cooperate to promote survival of drug-resistant glioma

Sci Signal. 2010 Nov 9;3(147):ra81. doi: 10.1126/scisignal.2001017.

Abstract

Although the phosphatidylinositol 3-kinase to Akt to mammalian target of rapamycin (PI3K-Akt-mTOR) pathway promotes survival signaling, inhibitors of PI3K and mTOR induce minimal cell death in PTEN (phosphatase and tensin homolog deleted from chromosome 10) mutant glioma. Here, we show that the dual PI3K-mTOR inhibitor PI-103 induces autophagy in a form of glioma that is resistant to therapy. Inhibitors of autophagosome maturation cooperated with PI-103 to induce apoptosis through the mitochondrial pathway, indicating that the cellular self-digestion process of autophagy acted as a survival signal in this setting. Not all inhibitors of mTOR synergized with inhibitors of autophagy. Rapamycin delivered alone induced autophagy, yet cells survived inhibition of autophagosome maturation because of rapamycin-mediated activation of Akt. In contrast, adenosine 5'-triphosphate-competitive inhibitors of mTOR stimulated autophagy more potently than did rapamycin, with inhibition of mTOR complexes 1 and 2 contributing independently to induction of autophagy. We show that combined inhibition of PI3K and mTOR, which activates autophagy without activating Akt, cooperated with inhibition of autophagy to cause glioma cells to undergo apoptosis. Moreover, the PI3K-mTOR inhibitor NVP-BEZ235, which is in clinical use, synergized with the lysosomotropic inhibitor of autophagy, chloroquine, another agent in clinical use, to induce apoptosis in glioma xenografts in vivo, providing a therapeutic approach potentially translatable to humans.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autophagy / drug effects*
  • Cell Line, Tumor
  • Chloroquine / metabolism
  • Chloroquine / pharmacology
  • Drug Synergism
  • Flow Cytometry
  • Furans / pharmacology*
  • Glioma / drug therapy*
  • Glioma / genetics
  • Glioma / metabolism*
  • Histological Techniques
  • Humans
  • Imidazoles / metabolism
  • Imidazoles / pharmacology
  • Immunoblotting
  • Immunohistochemistry
  • Mice
  • Mice, Inbred BALB C
  • Microscopy, Confocal
  • Mitochondria / metabolism
  • Mutation / genetics
  • Oncogene Protein v-akt / metabolism*
  • PTEN Phosphohydrolase / genetics
  • Phosphoinositide-3 Kinase Inhibitors
  • Pyridines / pharmacology*
  • Pyrimidines / pharmacology*
  • Quinolines / metabolism
  • Quinolines / pharmacology
  • Sirolimus / pharmacology
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / metabolism*
  • Transplantation, Heterologous

Substances

  • Furans
  • Imidazoles
  • PI103
  • Phosphoinositide-3 Kinase Inhibitors
  • Pyridines
  • Pyrimidines
  • Quinolines
  • Chloroquine
  • Oncogene Protein v-akt
  • TOR Serine-Threonine Kinases
  • PTEN Phosphohydrolase
  • dactolisib
  • Sirolimus